Engineering GPCR Targets via Directed Evolution to Discover Pharmacologically Active Antibodies & Small-Molecule Modulators
9:00 am - Thursday 30th April 2026
- Enabling the discovery of inverse agonist antibodies with the EMP directed evolution platform: shifting the paradigm for CCR8 therapeutics
- Unlocking orphan receptors: discovery of inverse agonist small molecules to support target validation and therapeutic development
- Evolving conformationally biased receptor antigens for the discovery of agonistic antibodies
